Closed · W81XWH-21-PRARP-ADRA · CFDA 12.420 · Discretionary
DOD Peer Reviewed Alzheimer’s, Accelerating Diagnostics Research Award
Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- July 21, 2021
- Close date
- 1
- Expected awards
The verdict
DOD Peer Reviewed Alzheimer’s, Accelerating Diagnostics Research Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 1 expected award. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.
- Varies
- award range
- Closed
- application status
- 1
- expected award
- 12.420
- CFDA program
Archived opportunity record
DOD Peer Reviewed Alzheimer’s is closed (last close July 21, 2021). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed July 21, 2021
Est. Total Funding
$15,000,000
Expected Awards
1
Instrument
Grant
Description
The intent of the FY21 PRARP ADRA is to support high-impact, human-based development of robust diagnostic and/or prognostic biomarkers for military risk factors that pertain to AD/ADRD. It is anticipated that the proposed work will qualify clinically useful biomarkers for rapid transfer to clinical practice. The FY21 PRARP ADRA mechanism defines biomarker qualification as the evidentiary process of linking a biomarker with biological processes and clinical endpoints. Applications may consider elements of biomarker validation as part of the application. Biomarker validation is defined as assessing the biomarker’s measurement performance characteristics in terms of reproducibility, accuracy, precision, and limits of sensitivity. Applications that detail biomarker validation work should demonstrate how this research is relevant to overall biomarker qualification. As part of the application, the proposed biomarkers should demonstrate their potential for improved specificity and sensitivity with respect to diagnosis and/or prognosis of AD/ADRD as the study endpoint. The FY21 PRARP ADRA does not support basic discovery of biomarkers. As such, animal research is prohibited. The proposed biomarker for investigation must correlate with clinical endpoints to include cognition and/or behavior relevant to military risk factor-related research and AD/ADRD. As part of the application, the Principal Investigator (PI) should demonstrate that the study team has experience in both military risk factor-related research and AD/ADRD.The FY21 PRARP ADRA encourages applications to consider fluid-based, imaging-based, retinal, or wearable devices as potential diagnostics. Applications must provide a plan that demonstrates access to a suitable cohort and a plan for participant accrual. Suitable cohorts must be relevant to the military risk factor identified as part of the application. Due to nature of the FY21 PRARP ADRA, studies are required to prospectively recruit study participants. Applications must therefore describe how the anticipated outcome(s) can be attributable to the results of the proposed research (short-term gains), as well as consider the long-term scientific gains from the proposed research project. FY21 PRARP ADRA applications must be impact-based.
Catch-all / unrestricted eligibility mark · W81XWH-21-PRARP-ADRA
Grants.gov marks DOD Peer Reviewed Alzheimer’s with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).
- Code 99
- Unrestricted / see official listing
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
More from Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
DoW Neurofibromatosis Investigator-Initiated Research Award
DoW Neurofibromatosis Research Academy – Scholar Award
DoW Neurofibromatosis Exploration-Hypothesis Development Award
DOW Combat Readiness – Medical Research Program Translational Research Award
What to do next
DOD Peer Reviewed Alzheimer’s is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- Compare award ranges across federal categories before you pick a single CFDA. All categories
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |